Brief: Alumis Announces Late-Breaker Oral Presentation Of Phase 3 Data For Envudeucitinib In Moderate-To-Severe Plaque Psoriasis At 2026 American Academy Of Dermatology Annual Meeting
18/03/2026 12:02
March 18 (Reuters) - Alumis Inc ALMS.O: ALUMIS ANNOUNCES LATE-BREAKER ORAL PRESENTATION OF PHASE 3 DATA FOR ENVUDEUCITINIB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS AT 2026 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING Source text: ID:nGNX65rgTr Further company coverage: ALMS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alumis
See all newsBrief: Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data
U.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Alumis set for worst day after lupus drug misses main goal in mid-stage trial
Alumis eyes late-stage lupus study despite trial miss (updated)
Alumis tumbles after lupus drug misses main goal in mid-stage trial